Open AccessSevere eosinophilic asthma: therapeutic potential of Reslizumab
Author(s) -
Р. С. Фассахов
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-15-70-75
Subject(s) - asthma , mepolizumab , medicine , eosinophilic , monoclonal antibody , immunology , interleukin 5 , intensive care medicine , interleukin , eosinophil , pathology , antibody , cytokine
The review discusses the problems associated with the treatment of patients with severe resistant to therapy asthma: prevalence, socio-economic burden, impact on quality of life. The phenotype of bronchial asthma with eosinophilic inflammation, frequency of occurrence, clinical features, and modern approaches to therapy are discussed in detail, including the use of a drug of monoclonal antibodies against interleukin 5-reslizumab.